MRM
MEDIROM Healthcare Technologies Inc. (MRM) Business Model Analysis (2026)
Overall Score
Revenue Quality
Revenue base remains sizable, with revenue per share at 476.2 and price-to-sales at 0.20, indicating the market is valuing the business cheaply relative to sales.
Gross margin is 25.3%, but profitability is weak with EBIT margin at -19.8% and net margin at -16.1%.
Profitability
Returns are deeply negative, with ROA at -14.6%, ROE at -68.4%, and ROIC at -19.3%.
Operating cash flow and free cash flow are both negative, with OCF per share at -43.3 and FCF per share at -45.3.
Balance Sheet
Liquidity is acceptable with a current ratio of 1.75 and quick ratio of 1.75, supporting near-term obligations.
Leverage remains elevated, with debt-to-equity at 1.75 and debt-to-assets at 56.1%, while cash per share is only 2.55.
Cash Flow
Cash generation is negative, with operating cash flow ratio at -0.17 and free cash flow yield at -48.8%.
Capital spending is light relative to revenue, but it is not enough to offset weak operating performance and negative free cash flow.
Capital Efficiency
Asset turnover is 0.91, but returns on capital remain poor, with return on capital employed at -35.2% and return on invested capital at -19.3%.
Working capital efficiency is weak, with days sales outstanding at 342.1 and a cash conversion cycle of 313.0 days.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on MEDIROM Healthcare Technologies Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

